fda warning letters compounded semaglutide tirzepatide september 2025 There's lots going on this month at in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Important Notice: Tirzepatide Compounding Update
Description
Your provider should work with you to determine the right timeline and help you transition to a maintenance plan once you've reached your target weight
Clinical trials demonstrated infrequent hypoglycemia with tirzepatide alone, but risk increases substantially when combined with insulin or sulfonylureas
The quality of compounding matters enormously
On average, patients can see up to a 24% reduction in fat after a full treatment cycle
Survodutide : Phase 2 MASH trial showed 62% MASH resolution at 4.8 mg vs 14% placebo
We do not use peptides extracted from animal or human tissues
